Engaging with Bispecific T-Cell Engagers
Last Updated: May 16, 2025
An overview of how these agents’ function, their dosing schedules, notable side effects, and the Risk Evaluation and Mitigation Strategies (REMS) requirements for certain agents.
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Up Close with Linvoseltamab
Last Updated: 10/10/2025
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 10/10/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 10/10/2025
Example SOPs and Documents: Bispecific T-Cell Engager Ordering and REMS Compliance
Last Updated: 10/10/2025
PQI in Action
Treatment Discussion Guides
Patient Education Sheet
Patient Education Sheet
PQI in Action: Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 10/10/2025
Nirogacestat (Ogsiveo): Treatment Discussion Guide
Last Updated: 10/10/2025
Vorasidenib
Last Updated: 10/10/2025
Encorafenib and Binimetinib
Last Updated: 10/10/2025